FER and pancreatic ductal adenocarcinoma: Thus, the ability to simultaneously target through a selective Fer/FerT inhibitor, mitochondrial and nuclear metabolic processes may underlie the dramatic cytotoxic effect obtained when aggressive malignant cells such as metastatic and pancreatic ductal adenocarcinoma cells (PDAC) are being treated with the selective Fer/FerT inhibitor, E260 [25].